Design of experiments

Global Atrial Fibrillation Clinical Trials Review Report - H1, 2021 - ResearchAndMarkets.com

Friday, July 30, 2021 - 12:46pm

The "Atrial Fibrillation - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atrial Fibrillation - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Atrial Fibrillation Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Atrial Fibrillation.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Immuno-oncology Clinical Trials Market Research Report 2021: Analysis by Phase (Phase I, Phase II, Phase III, Phase IV), Design (Interventional Trials, Observational Trials), & Indication - ResearchAndMarkets.com

Thursday, July 29, 2021 - 5:06pm

The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, Phase IV), by Design (Interventional Trials, Observational Trials), by Indication, by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global immuno-oncology clinical trials market size is expected to reach USD 15.1 billion by 2028.
  • The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.
  • At the end of 2019, over 40.0% of current immuno-oncology clinical experiments involved at least one location in the region
    Chapter 3 Immuno-oncology clinical trials Market: Variables, Trends, & Scope
    Chapter 4 Immuno-oncology Clinical Trials Market: Phase Segment Analysis
    4.1 Immuno-oncology Clinical Trials Market: Phase Market Share Analysis, 2020 & 2028

Gonorrhea Clinical Trials Review, H2 2021 Research Report - ResearchAndMarkets.com

Thursday, July 29, 2021 - 12:27pm

The "Gonorrhea - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gonorrhea - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Gonorrhea - Global Clinical Trials Review, H2, 2021" provides an overview of the Gonorrhea Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Gonorrhea.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Gonorrhea to Infectious Disease Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Gonorrhea to Infectious Disease Clinical Trials

Global Gallbladder Cancer Clinical Trials Review, H2 2021 - ResearchAndMarkets.com

Thursday, July 29, 2021 - 12:17pm

The "Gallbladder Cancer - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Gallbladder Cancer - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Gallbladder Cancer - Global Clinical Trials Review, H2, 2021" provides an overview of the Gallbladder Cancer Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Gallbladder Cancer.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Gallbladder Cancer to Oncology Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Gallbladder Cancer to Oncology Clinical Trials

Global Graves' Ophthalmopathy Disease Clinical Trials Review: H1, 2021 - ResearchAndMarkets.com

Thursday, July 29, 2021 - 11:10am

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

Key Points: 
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level

Global Fabry Disease Clinical Trials Review, H2 2021 Report - ResearchAndMarkets.com

Thursday, July 29, 2021 - 9:16am

The "Fabry Disease - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fabry Disease - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Fabry Disease - Global Clinical Trials Review, H2, 2021" provides an overview of the Fabry Disease Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Fabry Disease.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Fabry Disease to Genetic Disorders Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Fabry Disease to Genetic Disorders Clinical Trials

Global Dental Pain (Toothache Tooth Pain) Clinical Trials Review, H2 2021 Research Report - ResearchAndMarkets.com

Thursday, July 29, 2021 - 8:53am

The "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Dental Pain (Toothache Tooth Pain) - Global Clinical Trials Review, H2, 2021" provides an overview of the Dental Pain (Toothache Tooth Pain) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Dental Pain (Toothache Tooth Pain).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Dental Pain (Toothache/Tooth Pain) to Central Nervous System Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Dental Pain (Toothache/Tooth Pain) to Central Nervous System Clinical Trials

Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology

Wednesday, July 28, 2021 - 1:00pm

Cumulative 24-week AF burden was 24.4% (95% CI: 18.5, 30.2) for bucindolol and 36.7% (95% CI: 30.0, 43.5) for metoprolol (36% reduction, p =0.002).

Key Points: 
  • Cumulative 24-week AF burden was 24.4% (95% CI: 18.5, 30.2) for bucindolol and 36.7% (95% CI: 30.0, 43.5) for metoprolol (36% reduction, p =0.002).
  • AF burden is increasingly being recognized as a more sensitive measure of arrhythmia that is closely linked to key clinical outcomes.
  • In the GENETIC-AF Phase 2b clinical trial device substudy and in the entire trial cohort, Gencaro demonstrated favorable treatment effects compared to the comparator arm.
  • The U.S. FDA has granted Fast Track designation to the rNAPc2 development program, currently in Phase 2 clinical testing.

Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum

Wednesday, July 28, 2021 - 1:05pm

DURHAM, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the last patient has completed their planned Week-24 follow-up visit in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical gel with antiviral properties for the treatment of molluscum contagiosum (“molluscum”).

Key Points: 
  • Tomoko Maeda-Chubachi, M.D., Ph.D., M.B.A., Senior Vice President, Medical at Novan commented, The completion of all Week-24 patient visits is an exciting step forward towards bringing a promising treatment option to molluscum patients.
  • B-SIMPLE4 is a multi-center, double-blind, randomized, vehicle-controlled study that exceeded its enrollment target by randomizing 891 patients (1:1 randomization) in the study, across 55 clinical sites.
  • Patients were treated for up to 12 weeks with a follow-up visit at Week 24.
  • The Companys lead product candidate is SB206, a topical gel with antiviral properties, for the treatment of molluscum.

Panbela Schedules Conference Call on August 11, 2021, to Report 2021 Second Quarter Financial Results

Wednesday, July 28, 2021 - 2:00pm

In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression or peripheral neuropathy, which can be chemotherapy-related adverse events.

Key Points: 
  • In data evaluated from clinical studies to date, SBP-101 has not shown exacerbation of bone marrow suppression or peripheral neuropathy, which can be chemotherapy-related adverse events.
  • The safety data and PMI profile observed in the current Panbela sponsored clinical trial generally provides support for continued evaluation of SBP-101 in a randomized clinical trial.
  • Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs.
  • Our actual results and financial condition may differ materially and adversely from the forward-looking statements.